Pancreatic cancer symptoms are notoriously quiet at the start, which is the single most important thing to understand about this disease. The pancreas sits deep in the abdomen, behind the stomach, so a tumor can grow for months without pressing on anything that hurts. Most people eventually diagnosed describe vague changes first: less appetite, a nagging ache in the upper belly or back, unexplained weight loss, or blood sugar that suddenly stops behaving. In this article you will learn which signs deserve attention, why painless jaundice tends to be caught earlier, what a CA 19-9 blood test can and cannot do, how a diagnosis is confirmed, what the staging categories mean for treatment, and why digestion and nutrition matter more than most patients are told.
What pancreatic cancer is and why it is usually found late
The pancreas has two jobs. Its exocrine tissue makes digestive enzymes that break down fat, protein and starch; its endocrine tissue makes hormones, including insulin, that regulate blood sugar. Roughly nine in ten pancreatic cancers are pancreatic ductal adenocarcinoma, which starts in the ducts carrying those enzymes. A much smaller group, pancreatic neuroendocrine tumors, arise from hormone-producing cells and often grow slowly.
Late detection is anatomy plus biology, not carelessness. There is no approved screening test for the general population, no equivalent of a mammogram. The gland is surrounded by the stomach, small intestine, liver and major blood vessels, so a small tumor is invisible on routine imaging and silent on routine blood work. By the time symptoms are clear enough to prompt a scan, the disease has often spread beyond the pancreas.
Where the tumor sits changes what you feel
About two thirds of these tumors form in the head of the pancreas, the wider end nearest the small intestine, and the bile duct passes through it. A tumor there can squeeze the duct while still relatively small, which is why head tumors are sometimes found at a more treatable stage. Tumors in the body or tail have room to grow unnoticed and announce themselves later, usually with back pain, weight loss or new diabetes rather than yellowing.
Pancreatic cancer symptoms and what they may reflect
Almost every early symptom of this disease is also caused by something common and benign: indigestion, back strain, stress-related appetite loss, gallstones. The useful signal is not any single symptom but a cluster that persists, worsens, or appears without reason in someone over 50.
Painless jaundice, the presentation that gets caught earlier
Jaundice means yellowing of the skin and the whites of the eyes, caused by bilirubin backing up when bile cannot drain. Gallstones cause jaundice too, but they usually hurt. Jaundice without pain, often with dark urine, pale clay-colored stools and itchy skin, is treated as a red flag until proven otherwise. Blood work typically shows a rising conjugated bilirubin alongside a raised alkaline phosphatase. Anyone tracking these values can review a total bilirubin test result, and many also compare an alkaline phosphatase measurement.
New-onset diabetes after 50 with weight loss
This is the most under-known warning signal in pancreatic cancer. Developing diabetes for the first time after age 50, especially alongside unintentional weight loss, is a recognized risk marker. It runs backwards from how people expect cancer to work: the tumor disturbs how the pancreas handles glucose months before anything else appears. The combination is what matters, because type 2 diabetes usually develops in people who are gaining weight, not losing it. Diabetes that suddenly deteriorates after years of good control can carry the same meaning.
The framing matters too. The overwhelming majority of people who develop diabetes after 50 do not have pancreatic cancer, and population studies put the share diagnosed within three years at well under one in a hundred: too low to justify imaging everyone, high enough that doctors take notice when weight is dropping too. Glucose control is reviewed first, and many people track a fasting glucose result or a glycated hemoglobin value over time. Many also read a broader guide to diabetes symptoms and management.
Digestive changes, pain and other signs
Upper abdominal pain that radiates through to the middle of the back and eases when leaning forward is the classic description. Others include appetite loss, early fullness after small meals, nausea, new fat intolerance, and stools that turn pale, bulky, greasy and hard to flush. Some people develop a leg blood clot with no obvious cause, since this cancer raises clotting risk.
| Sign or symptom | Common benign explanations | Why doctors take it seriously |
|---|---|---|
| Yellow skin or eyes without pain | Gallstones, hepatitis, some medications | Painless obstruction of the bile duct needs urgent imaging |
| Upper belly pain going through to the back | Reflux, ulcer, muscular back pain, pancreatitis | Persistent, unexplained pain in this pattern warrants a scan |
| New diabetes after 50 with weight loss | Ordinary type 2 diabetes, medication effects | The combination of new diabetes and falling weight is a recognized risk marker |
| Pale, greasy, floating stools | Celiac disease, bile duct problems, infections | Suggests digestive enzymes or bile are not reaching the intestine |
| Unintentional weight loss over months | Thyroid disease, depression, diet change | Weight loss without a reason is investigated regardless of cause |
When to see a doctor
Book an appointment promptly if your skin or eyes turn yellow, if your urine darkens while your stools turn pale, if upper abdominal or mid-back pain lasts more than a couple of weeks without explanation, if you lose weight you were not trying to lose, or if you are diagnosed with diabetes after 50 while also losing weight. Bring dates and numbers: a doctor acts far faster on “eight pounds down since March, urine dark since last week” than on a general sense that something is off.
What a CA 19-9 blood test can and cannot tell you
CA 19-9 is the blood marker most associated with pancreatic cancer, and the most misunderstood. Three points settle most of the confusion.
It is not a screening test
CA 19-9 is not used to look for pancreatic cancer in people without symptoms, and no major guideline recommends it for that purpose. Its established role is monitoring: once cancer is confirmed, a baseline level helps gauge disease burden and repeat levels help judge whether treatment is working or whether disease has returned after surgery. A normal result does not rule pancreatic cancer out, and a high result on its own does not establish it. People who want the detail can review a full explanation of CA 19-9 blood test results.
It is falsely elevated by common benign conditions
The most frequent cause of a high CA 19-9 is not cancer at all. Any blockage of the bile ducts pushes the level up, including a simple gallstone. So do acute and chronic pancreatitis, cirrhosis, cholangitis, cystic fibrosis and several thyroid and gynecological conditions. This is why a level drawn while someone is jaundiced can be dramatically high, then fall once a stent relieves the obstruction, with no change in the tumor at all. Doctors read CA 19-9 in the context of imaging and liver chemistry, never alone. Many teams also follow a second marker and check a CEA blood test result.
Roughly 5 to 10 percent of people never produce it at all
CA 19-9 is built on a sugar structure tied to the Lewis blood group system, and making it requires a working enzyme encoded by the FUT3 gene. People who are Lewis-antigen negative, generally estimated at 5 to 10 percent of the population, lack that enzyme and cannot produce the marker no matter how much cancer is present. Their CA 19-9 stays low or undetectable throughout the illness, so the test is useless for monitoring and clinicians rely on imaging and symptoms instead. If your CA 19-9 has never risen despite a known diagnosis, this is very often the explanation, and it is worth asking your team about directly.
Risk factors, inherited syndromes and who is offered surveillance
Risk is not destiny, and most people with a risk factor never develop this cancer. Some associations are nonetheless consistent across large studies.
- Smoking, the strongest modifiable risk factor, roughly doubling risk, which falls again after quitting.
- Chronic pancreatitis, where years of inflammation and scarring raise risk substantially; hereditary pancreatitis raises it more. Many people first encounter acute pancreatitis and its warning signs.
- Long-standing type 2 diabetes, obesity, heavy alcohol use and a diet high in processed meat.
- Age, with most diagnoses after 65, although early-onset gastrointestinal cancers are rising in adults under 50.
- Family history, particularly two or more affected first-degree relatives, and inherited syndromes including BRCA1, BRCA2 and PALB2 variants, Lynch syndrome, familial atypical multiple mole melanoma and Peutz-Jeghers syndrome.
Surveillance exists, but only for these clearly defined high-risk groups. Expert guidance generally supports annual endoscopic ultrasound or magnetic resonance imaging for people with a strong family history or a known predisposing gene variant, usually starting around age 50, or ten years before the earliest age at which a relative was diagnosed; for syndromes such as Peutz-Jeghers or hereditary pancreatitis it may start between 35 and 40. Entry runs through genetic counseling, never worry alone. There is no demonstrated benefit to scanning average-risk adults, and the harms of false alarms are real.
How pancreatic cancer is diagnosed
Pancreas-protocol CT scanning
The first-line study is not an ordinary abdominal scan. A pancreas-protocol computed tomography scan uses contrast dye timed in specific phases and thin slices tuned to the pancreas and surrounding blood vessels. That detail matters because the relationship between the tumor and nearby arteries and veins determines whether surgery is possible. Magnetic resonance imaging complements it, particularly for liver spots and cystic lesions.
Endoscopic ultrasound with biopsy
Endoscopic ultrasound passes a probe on a flexible tube through the mouth into the stomach and duodenum, placing it millimeters from the pancreas. It finds small lesions that computed tomography can miss and lets a fine needle sample tissue in the same session. Tissue confirmation turns a suspicious scan into a diagnosis, and supplies material for molecular testing that can open specific treatment options.
Blood tests around the diagnosis
Blood work supports the picture rather than making the diagnosis. Liver chemistry maps the degree of bile duct obstruction, a baseline CA 19-9 is drawn once cancer is confirmed, nutritional status is assessed through markers including albumin, and anemia or clotting problems are checked before any procedure. At this stage people following their own results often review an albumin blood test result. If imaging shows spread, the liver is the commonest destination, which is why some patients are also handed a primary liver cancer overview. A deposit spreading from the pancreas is a different disease from a cancer that starts in the liver.
Staging: resectable, borderline, locally advanced, metastatic
Pancreatic cancer is described in numbered stages, but treatment decisions turn on four practical categories describing how the tumor relates to surrounding blood vessels and whether it has spread.
| Category | What it means | Usual treatment approach |
|---|---|---|
| Resectable | Tumor is confined to the pancreas and clear of critical arteries | Surgery, usually followed by chemotherapy; chemotherapy first in some centers |
| Borderline resectable | Tumor touches or partly surrounds a vessel that could still be reconstructed | Chemotherapy first, sometimes with radiation, then reassessment for surgery |
| Locally advanced | Tumor encases major arteries but has not spread to distant organs | Chemotherapy, sometimes radiation; a minority convert to operable disease |
| Metastatic | Cancer has reached the liver, lungs, abdominal lining or elsewhere | Systemic chemotherapy, targeted options where molecular testing applies, symptom control |
Treatment and living with the disease
Surgery is the only treatment that can remove the cancer entirely, and it is offered when the tumor is resectable or becomes resectable. For tumors in the head of the pancreas the operation is the Whipple procedure, which removes the pancreatic head, the duodenum, the gallbladder and part of the bile duct, then reconnects the digestive tract. Tumors in the body or tail are removed by distal pancreatectomy, often with the spleen. Outcomes are measurably better at high-volume hospitals, which is a fair question to ask before choosing a center.
Chemotherapy is the backbone for everyone else and is also given around surgery, with multi-drug combinations improving outcomes across stages over the past decade. Radiation is used selectively. Molecular testing of the tumor and germline genetic testing are now recommended for essentially all patients, because a minority carry alterations, including BRCA-related ones, that open specific drug options. Supportive care is not an afterthought: stenting a blocked bile duct, controlling nerve pain, preventing blood clots and managing blood sugar all change how people feel day to day. The National Cancer Institute publishes a detailed patient summary of treatment options by stage. Survival statistics are sobering, but they are averages that lag years behind current care; ask your own team what they mean for you.
Pancreatic exocrine insufficiency and nutrition
This is the part patients are least often warned about, and it materially affects how well someone feels. When a tumor blocks the pancreatic duct, or surgery removes pancreatic tissue, the gland can no longer deliver enough digestive enzymes to the intestine. That is pancreatic exocrine insufficiency. Fat passes through undigested, producing greasy, pale, foul-smelling stools that float, plus bloating, cramping, urgent bowel movements and steady weight loss even when someone is eating normally. It is common in pancreatic cancer and often mistaken for the cancer itself, for chemotherapy side effects, or for simple loss of appetite.
It is also treatable. Pancreatic enzyme replacement therapy supplies the missing enzymes in capsule form, taken with every meal and snack, at a dose matched to what the person actually eats. Dietitians address the fat-soluble vitamins A, D, E and K, poorly absorbed when fat digestion fails, and track weight and muscle mass. Diagnosis rests on symptoms plus a stool test of pancreatic enzyme output; people can interpret a fecal elastase test result. If you have greasy stools and are losing weight, raise it explicitly, because enzyme therapy is often under-prescribed and under-dosed.
Latest scientific advances
Research is moving in a specific direction: instead of hunting for one perfect blood test, groups are combining clues that already exist.
A large multicenter study published in 2026 tackled the Lewis-negative problem directly. Researchers sequenced genes in more than six hundred patients, confirmed that about one in ten cannot produce CA 19-9 at all, and showed that a very low result is itself a practical clue that someone is a nonproducer. Two further reviews, published in 2025 and 2026, reached a related conclusion: no single blood marker performs well enough alone, but combining CA 19-9 with markers such as CEA improves accuracy, and newer liquid biopsy methods, which look for fragments of tumor material circulating in blood, are being tested. What this means for you: if your CA 19-9 has stayed near zero despite a known diagnosis, that is a recognized biological pattern rather than a laboratory error; and any product marketed today as an early pancreatic cancer blood screen deserves skepticism.
Two studies from 2025 and 2026 focused on the diabetes signal. One offered magnetic resonance imaging to adults aged 50 and over with newly diagnosed or suddenly worsening diabetes and found one early-stage cancer, the first screen-detected early case reported in people without inherited risk. A second validated a scoring tool combining age at diabetes onset, weight change and blood sugar control. What this means for you: promising, but preliminary and not yet routine care, and the same research shows the large majority of people flagged do not have cancer. A companion 2026 review confirms that when suspicion is genuine, a pancreas-protocol computed tomography scan is the first test to request.
On treatment, a 2026 international overview describes progress on several fronts: multi-drug chemotherapy that works better across stages, surgical techniques that let some tumors once judged inoperable be removed after treatment, and early work on personalized vaccines and on drugs aimed at the KRAS gene alteration found in most of these tumors. What this means for you: the vaccine and KRAS approaches are experimental and reached mainly through clinical trials, but asking whether a trial fits your situation is worthwhile at any stage. Separately, an international guideline published in late 2024 confirmed that enzyme replacement plus dietary support is the cornerstone of care for exocrine insufficiency, and should begin on symptoms rather than wait for perfect test results.
Glossary
| Term | Definition |
|---|---|
| Adenocarcinoma | A cancer that starts in gland or duct cells. Pancreatic ductal adenocarcinoma accounts for about nine in ten pancreatic cancers. |
| CA 19-9 | Carbohydrate antigen 19-9, a substance measured in blood. It is used to monitor known pancreatic cancer, not to screen healthy people. |
| Lewis antigen status | A blood group trait that determines whether a person can produce CA 19-9 at all. Around 5 to 10 percent of people cannot. |
| Jaundice | Yellowing of the skin and the whites of the eyes caused by bilirubin building up, usually because bile cannot drain normally. |
| Endoscopic ultrasound | An ultrasound probe passed through the mouth into the stomach and duodenum, close enough to the pancreas to see small lesions and take a biopsy. |
| Resectable | A tumor that surgeons judge removable in full, because it has not grown around the major arteries or spread to distant organs. |
| Neoadjuvant therapy | Treatment such as chemotherapy given before surgery, often to shrink a tumor away from blood vessels so it can be removed. |
| Whipple procedure | The operation used for tumors in the head of the pancreas. It removes the pancreatic head, duodenum, gallbladder and part of the bile duct. |
| Pancreatic exocrine insufficiency | A shortage of digestive enzymes reaching the intestine, causing greasy stools, bloating, poor nutrient absorption and weight loss. |
| Pancreatic enzyme replacement therapy | Capsules of digestive enzymes taken with meals and snacks to replace what the pancreas can no longer supply. |
Frequently asked questions
What are the very first symptoms most people notice?
Most people describe something unremarkable rather than dramatic. The commonest first changes are appetite loss, a dull ache high in the abdomen or through to the back, fatigue, and weight coming off without effort. Some notice that fatty food no longer sits well, or that stools have become pale and greasy. Yellowing of the eyes or skin appears earlier when the tumor sits in the head of the pancreas and presses on the bile duct, and later or not at all when it sits in the body or tail. Because these changes are so ordinary, the pattern that matters is persistence over weeks combined with something unexplained, such as weight loss or new diabetes.
Are the symptoms different in women and men?
The symptoms themselves are essentially the same. Jaundice, upper abdominal and back pain, weight loss, appetite loss and digestive change occur in both. Incidence is slightly higher in men, largely reflecting historical differences in smoking rates. What can differ is interpretation: abdominal pain and fatigue in women are sometimes attributed to gynecological or hormonal causes first, which occasionally delays imaging. If symptoms persist without a confirmed explanation, it is reasonable to ask directly whether the pancreas has been looked at.
What is the single biggest cause of pancreatic cancer?
There is no single cause, but smoking is the largest avoidable contributor, associated with roughly double the risk. Risk declines after quitting and continues to fall over the following years. Other significant contributors include chronic pancreatitis, obesity, long-standing type 2 diabetes and heavy alcohol use, along with inherited gene variants in a minority of cases. Most people who develop pancreatic cancer have no identifiable single cause, which is why the disease is better understood as an accumulation of risk rather than one triggering event.
What are the signs that pancreatic cancer has spread?
Spread most often reaches the liver, the lining of the abdomen, or the lungs. Signs can include jaundice that appears or worsens, a swollen abdomen from fluid buildup, worsening pain, breathlessness, marked fatigue and continuing weight loss. These signs are not specific and can also reflect treatment effects, infection or exocrine insufficiency, so they are always assessed with imaging rather than assumed. Anyone experiencing a clear change in symptoms should report it to their oncology team promptly rather than waiting for the next scheduled appointment.
Can a blood test find pancreatic cancer early?
Not reliably, and no blood test is currently approved for that purpose. CA 19-9 misses cancers in the 5 to 10 percent of people who cannot produce it, rises for many benign reasons, and can be normal in early disease. Research into combined marker panels and liquid biopsy is active and promising, but none of it has yet become routine screening. Early detection today depends on recognizing symptom patterns, investigating unexplained weight loss and new diabetes after 50, and offering imaging surveillance to people with a strong inherited or family risk.
What do survival statistics actually mean for one person?
Published survival figures are averages drawn from large groups diagnosed several years ago, so they cannot reflect current treatment or your individual situation. They mix every stage together unless stated otherwise, and they take no account of age, fitness, tumor biology or whether surgery was possible. They are useful for measuring progress across a health system and poor at predicting one person’s course. The more useful conversation is with your own oncologist about your stage, your treatment plan and what to expect over the coming months.
Sources
- National Cancer Institute — Pancreatic Cancer Treatment (PDQ), Patient Version — NIH, 2026 — cancer.gov
- Mayo Clinic — Pancreatic cancer: symptoms and causes — Mayo Clinic, 2026 — mayoclinic.org
- MedlinePlus — Pancreatic Cancer — National Library of Medicine, 2026 — medlineplus.gov
- Yeh CM, Yu CC, Lee AF, et al. — A New CA19-9 Cutoff Value Identifies Lewis Antigen Status and Refines Prognostic Stratification in PDAC — Clinical Cancer Research, 2026 — doi.org/10.1158/1078-0432.CCR-25-4564
- Wang L, Chen Z, He X, Kong X, Xiong Y — Research progress on early diagnostic markers for pancreatic cancer — World Journal of Surgical Oncology, 2026 — doi.org/10.1186/s12957-026-04215-8
- Liu Y, Zhang J, Zheng Z, et al. — The Interplay Between CA19-9 and the Lewis Blood Group System — Canadian Journal of Gastroenterology and Hepatology, 2025 — doi.org/10.1155/cjgh/8465615
- Frank RC, Shim B, Lo T, et al. — Pancreatic Cancer Screening in New-onset and Deteriorating Diabetes: Preliminary Results From the PANDOME Study — Journal of Clinical Endocrinology and Metabolism, 2025 — doi.org/10.1210/clinem/dgaf319
- Huang K, Huang Z, He Y, Zhao P, Hu X — New-Onset Diabetes and Pancreatic Ductal Adenocarcinoma: Implications for Early Recognition and Clinical Management — Diabetes/Metabolism Research and Reviews, 2026 — doi.org/10.1002/dmrr.70205
- Price CA, Claridge H, de Lusignan S, et al. — Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC): external validation using English sentinel network — British Journal of General Practice, 2026 — doi.org/10.3399/BJGP.2024.0253
- Mohamed G, Munir M, Rai A, Gaddam S — Pancreatic Cancer: Screening and Early Detection — Gastroenterology Clinics of North America, 2024 — doi.org/10.1016/j.gtc.2024.09.006
- Dominguez-Munoz JE, Vujasinovic M, de la Iglesia D, et al. — European guidelines for the diagnosis and treatment of pancreatic exocrine insufficiency — United European Gastroenterology Journal, 2024 — doi.org/10.1002/ueg2.12674
- Roth S, Apte M, Balachandran VP, et al. — Pancreatic cancer — Nature Reviews Disease Primers, 2026 — doi.org/10.1038/s41572-026-00699-6
Further reading
- Understand a complete blood count panel
- Interpret a direct bilirubin measurement
- Review a prealbumin nutritional marker
- Decode a stool report showing fat droplets in the stool
- Review colorectal cancer symptoms and risk factors
Understand your lab results with BloodSense
Pancreatic disease shows up across a lab report long before anyone uses the word cancer: bilirubin and alkaline phosphatase climbing together when bile cannot drain, blood sugar and glycated hemoglobin drifting upward in someone losing weight, albumin slipping as nutrition suffers, a stool enzyme test pointing to poor fat digestion. BloodSense reads those results with you in plain language, explains what each value measures and why it may be outside its reference range, and helps you arrive at your appointment with clear questions. It helps you understand your results; it does not diagnose, and it does not replace your doctor.
